Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
- Author
- WONG, Harvey1 ; VERNILLET, Laurent2 ; HOEFLICH, Klaus P4 ; YONGCHANG SHI5 ; AFTAB, Blake T5 ; AOYAMA, Ron5 ; TAN LAM, Sanh5 ; BELVIN, Marcia4 ; PRESCOTT, John3 ; PETERSON, Amy3 ; WARE, Joseph A2 ; LEE, Lillian5 ; MARTINI, Jean-Francois5 ; PEIWEN YU5 ; CONGFEN LI5 ; DEL ROSARIO, Geoffrey5 ; CHOO, Edna F1
[1] Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., United States
[2] Department of Clinical Pharmacology, Genentech Inc., United States
[3] Department of Exploratory Clinical Development, Genentech Inc., United States
[4] Department of Cell Signaling Pathways, Genentech Inc., United States
[5] Exelixis, South San Francisco, California, United States - Source
Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, 10 p ; ref : 36 ref
- CODEN
- CCREF4
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Analyse Essai préclinique Gap Inhibiteur Relation pharmacocinétique pharmacodynamie
- Keyword (en)
- Analysis Preclinical trial Gap Inhibitor Pharmacokinetic pharmacodynamic relationship
- Keyword (es)
- Análisis Ensayo preclínico Hiato Inhibidor Relación farmacocinética farmacodinamia
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25944960
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-12-0445 
https://dx.doi.org/10.1158/1078-0432.CCR-12-0445
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"3090\";s:8:\"\u0000*\u0000epage\";s:4:\"3099\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"WONG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Harvey\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:18:\"VERNILLET, Laurent\";i:1;s:17:\"HOEFLICH, Klaus P\";i:2;s:13:\"YONGCHANG SHI\";i:3;s:14:\"AFTAB, Blake T\";i:4;s:11:\"AOYAMA, Ron\";i:5;s:13:\"TAN LAM, Sanh\";i:6;s:14:\"BELVIN, Marcia\";i:7;s:14:\"PRESCOTT, John\";i:8;s:13:\"PETERSON, Amy\";i:9;s:14:\"WARE, Joseph A\";i:10;s:12:\"LEE, Lillian\";i:11;s:22:\"MARTINI, Jean-Francois\";i:12;s:9:\"PEIWEN YU\";i:13;s:10:\"CONGFEN LI\";i:14;s:21:\"DEL ROSARIO, Geoffrey\";i:15;s:12:\"CHOO, Edna F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"3090\";s:8:\"\u0000*\u0000epage\";s:4:\"3099\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"WONG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Harvey\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:18:\"VERNILLET, Laurent\";i:1;s:17:\"HOEFLICH, Klaus P\";i:2;s:13:\"YONGCHANG SHI\";i:3;s:14:\"AFTAB, Blake T\";i:4;s:11:\"AOYAMA, Ron\";i:5;s:13:\"TAN LAM, Sanh\";i:6;s:14:\"BELVIN, Marcia\";i:7;s:14:\"PRESCOTT, John\";i:8;s:13:\"PETERSON, Amy\";i:9;s:14:\"WARE, Joseph A\";i:10;s:12:\"LEE, Lillian\";i:11;s:22:\"MARTINI, Jean-Francois\";i:12;s:9:\"PEIWEN YU\";i:13;s:10:\"CONGFEN LI\";i:14;s:21:\"DEL ROSARIO, Geoffrey\";i:15;s:12:\"CHOO, Edna F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"3090\";s:8:\"\u0000*\u0000epage\";s:4:\"3099\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"WONG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Harvey\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:18:\"VERNILLET, Laurent\";i:1;s:17:\"HOEFLICH, Klaus P\";i:2;s:13:\"YONGCHANG SHI\";i:3;s:14:\"AFTAB, Blake T\";i:4;s:11:\"AOYAMA, Ron\";i:5;s:13:\"TAN LAM, Sanh\";i:6;s:14:\"BELVIN, Marcia\";i:7;s:14:\"PRESCOTT, John\";i:8;s:13:\"PETERSON, Amy\";i:9;s:14:\"WARE, Joseph A\";i:10;s:12:\"LEE, Lillian\";i:11;s:22:\"MARTINI, Jean-Francois\";i:12;s:9:\"PEIWEN YU\";i:13;s:10:\"CONGFEN LI\";i:14;s:21:\"DEL ROSARIO, Geoffrey\";i:15;s:12:\"CHOO, Edna F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"3090\";s:8:\"\u0000*\u0000epage\";s:4:\"3099\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"WONG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Harvey\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:18:\"VERNILLET, Laurent\";i:1;s:17:\"HOEFLICH, Klaus P\";i:2;s:13:\"YONGCHANG SHI\";i:3;s:14:\"AFTAB, Blake T\";i:4;s:11:\"AOYAMA, Ron\";i:5;s:13:\"TAN LAM, Sanh\";i:6;s:14:\"BELVIN, Marcia\";i:7;s:14:\"PRESCOTT, John\";i:8;s:13:\"PETERSON, Amy\";i:9;s:14:\"WARE, Joseph A\";i:10;s:12:\"LEE, Lillian\";i:11;s:22:\"MARTINI, Jean-Francois\";i:12;s:9:\"PEIWEN YU\";i:13;s:10:\"CONGFEN LI\";i:14;s:21:\"DEL ROSARIO, Geoffrey\";i:15;s:12:\"CHOO, Edna F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-0445\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"3090\";s:8:\"\u0000*\u0000epage\";s:4:\"3099\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"WONG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Harvey\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:18:\"VERNILLET, Laurent\";i:1;s:17:\"HOEFLICH, Klaus P\";i:2;s:13:\"YONGCHANG SHI\";i:3;s:14:\"AFTAB, Blake T\";i:4;s:11:\"AOYAMA, Ron\";i:5;s:13:\"TAN LAM, Sanh\";i:6;s:14:\"BELVIN, Marcia\";i:7;s:14:\"PRESCOTT, John\";i:8;s:13:\"PETERSON, Amy\";i:9;s:14:\"WARE, Joseph A\";i:10;s:12:\"LEE, Lillian\";i:11;s:22:\"MARTINI, Jean-Francois\";i:12;s:9:\"PEIWEN YU\";i:13;s:10:\"CONGFEN LI\";i:14;s:21:\"DEL ROSARIO, Geoffrey\";i:15;s:12:\"CHOO, Edna F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
